Ligand Pharmaceuticals CEO John Higgins' 2019 pay rises 7% to $6.8M
Ligand Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: November 12, 2020
Ligand Pharmaceuticals reported fiscal year 2019 executive compensation information on November 12, 2020.
In 2019, four executives at Ligand Pharmaceuticals received on average a compensation package of $4.2M, a 18% increase compared to previous year.
Average pay of disclosed executives at Ligand Pharmaceuticals
John L. Higgins, Chief Executive Officer, received $6.8M in total, which increased by 7% compared to 2018. 43% of Higgins' compensation, or $2.9M, was in stock awards. Higgins also received $292K in non-equity incentive plan, $2.9M in option awards, $648K in salary, as well as $6K in other compensation.
For fiscal year 2019, the median employee pay was $109,795 at Ligand Pharmaceuticals. Therefore, the ratio of John L. Higgins' pay to the median employee pay was 62 to one.
Matthew W. Foehr, Chief Operating Officer, received a compensation package of $4.2M, which increased by 28% compared to previous year. 40% of the compensation package, or $1.7M, was in stock awards.
Matthew Korenberg, Chief Financial Officer, earned $3.6M in 2019, a 34% increase compared to previous year.
Charles S. Berkman, General Counsel, received $2M in 2019, which increases by 16% compared to 2018.
Related executives
You may also like
Source: SEC filing on November 12, 2020.